Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-03-11
2010-10-05
Falk, Anne-Marie (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S009100, C424S009200
Reexamination Certificate
active
07807618
ABSTRACT:
Disclosed are methods for delivering an enzyme to a subject's brain or bone. The methods include administering a hyaluronidase to the subject and administering the enzyme to the subject. The hyaluronidase and the enzyme are administered to the subject under conditions effective to deliver the enzyme to the subject's brain or bone. Compositions and kits which include hyaluronidase and an enzyme are also disclosed, as are methods for increasing blood-brain barrier permeability in a subject. Also disclosed are methods, compositions, and kits for delivering genes or other nucleic acid molecules to a subject's brain or bone, as well as methods, compositions, and kits for delivering enzymes to a subject's tissues. The methods, compositions, and kits are disclosed as being useful in treating or preventing a variety of enzyme deficiency diseases, such as those affecting brain and/or bone, e.g., as Canavan's disease, Fabry disease, Gaucher's disease, various forms of mucopolysaccharidosis (e.g., Hurler's syndrome, Scheie syndrome, Hurler-Scheie syndrome, Sanfillippo A syndrome, Morquio A syndrome, Morquio B syndrome, etc.), Niemann-Pick disease, Schindler disease, and Pompe disease.
REFERENCES:
patent: 4524065 (1985-06-01), Pinnell
patent: 4568543 (1986-02-01), Borrelli et al.
patent: 4645668 (1987-02-01), Pinnell
patent: 4820516 (1989-04-01), Sawyer et al.
patent: 5116615 (1992-05-01), Gokcen et al.
patent: 5739118 (1998-04-01), Carrano et al.
patent: 5854046 (1998-12-01), Au-Young et al.
patent: 6114161 (2000-09-01), Truog et al.
patent: 6171575 (2001-01-01), Okuyama
patent: 6193963 (2001-02-01), Stern et al.
patent: 6214978 (2001-04-01), Truog et al.
patent: 6258791 (2001-07-01), Braun
patent: 6296847 (2001-10-01), Gokcen et al.
patent: 2003/0170243 (2003-09-01), Stern et al.
patent: 0 263 417 (1987-09-01), None
patent: WO 99/29841 (1999-06-01), None
patent: WO 00/52149 (2000-09-01), None
Dietz and Bahr (2004) Delivery of bioactive molecules into the cell: the Trojan horse approach. Molecular and Cellular Neuroscience 27: 85-131.
Emerich, DF (2000) Recent efforts to overcome the blood-brain barrier for drug delivery. Expert Opinion on Therapeutic Patents 10(3): 279-287.
Gao et al. (1997) The therapeutic potentials of neurotrophic factors for diseases of the nervous system. Expert Opinion on Therapeutic Patents 7(4): 325-338.
Pardridge, WM (1997) Drug delivery to the brain. Journal of Cerebral Blood Flow and Metabolism 17: 713-731.
Robert et al. “Action of Proteolytic and Glycolytic Enzymes on the Permeability of the Blood-Brain Barrier,”Biomedicine, 21(l):36-39 (1974).
Dubensky et al., “Direct Transfection of Viral and Plasmid DNA into the Liver or Spleen of Mice,”Proc. Natl. Acad. Sci. U.S.A., 81(23):7529-7533 (1984).
Hermann et al., “Gaucher Disease: An Assessment of Skeletal Involvement and Therapeutic Responses to Enzyme Replacement,”Skeletal Radiol., 26(12):687-696 (1997).
Fromes et al., “Gene Delivery to the Myocardium by Intrapericardial Injection,”Gene Ther., 6(4):683-688 (1999).
Vellodi et al., “Management of Neuropathic Gaucher Disease: A European Consensus,”J. Inherit. Metab. Dis., 24(3):319-327 (2001).
Senitz et al., “Intravenous Application of Hylase ‘Dessau’—Experimental Studies in Rats. Early Reactions in Plexus Chorioideus and Ependyma,”Exp. Pathol. (Jena), 6(1):47-49 (1972).
Senitz et al., “Intravenous Application of Hylase ‘Dessau’—Experimental Studies in Rats. Effect of Hylase ‘Dessau’ on the Blood Brain Barrier,”Exp. Pathol. (Jena), 7(5):228-233 (1972).
Orkin et al., “Isolation and Characterization of Hyaluronidase from Cultures of Chick Embryo Skin- and Muscle-Derived Fibroblasts,”J. Biol. Chem., 255(3):1036-1042 (1980).
Triggs-Raine et al., “Mutations in HYAL1, a Member of a Tandemly Distributed Multigene Family Encoding Disparate Hyaluronidase Activities, Cause a Newly Described Lysosomal Disorder, Mucopolysaccharidosis IX,”Proc. Natl. Acad. Sci. U.S.A.,96(11):6296-6300 (1999).
O'Brien, “The Lysosomal Storage Diseases,”Mayo Clinic Proceedings, 57(3):192-193 (1982).
Yew et al., “Gene Therapy for Lysosomal Storage Disorders,”Current Opinion in Molecular Therapeutics, 3(4):399-406 (2001).
Adler Benjamin Aaron
Falk Anne-Marie
The Board of Regents of the University of Texas System
LandOfFree
Methods and compositions for delivering enzymes and nucleic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for delivering enzymes and nucleic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for delivering enzymes and nucleic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4222901